Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Coordination of stress-adaptive cell states by CRIPTO in breast cancer heterogeneity and progression

Award Number: R01CA289704
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2025
PERIOD OF PERFORMANCE END DATE: 01/31/2030

Group Awards By:

View Award Description

Coordination of stress-adaptive cell states by CRIPTO in breast cancer heterogeneity and progression - Cellular heterogeneity in cancer represents a major challenge to the development of curative therapies, as even small subsets of cells can fuel relapse, dormancy, treatment failure, and metastasis. Cellular plasticity i.e. reversible state change, likely provides a key contributing mechanism. However, clinical approaches that specifically target molecular mediators of cellular plasticity are lacking. This proposal investigates the CR1 pathway as a critical plasticity mediator in breast cancer progression. CR1 is a cell surface/secreted stem cell factor and oncofetal protein that promotes proliferation, migration and epithelial-mesenchymal transition in human mammary epithelial cells in vitro and stem cell maintenance in primary mouse mammary epithelial cells cultured ex vivo. Recently, we showed that inhibition of CR1 with a candidate, engineered, peptide therapeutic (ALK4L75A-Fc a.k.a. A4Fc) reduced growth of human breast cancer cells under nutrient stress, and blocked metastasis when these were transplanted into mice. CR1 blockade in these tumor models is associated with reduced fibrosis -- consistent with the discovery of CR1 as a key regulator of fibrosis in wounding. We now seek to understand molecular mechanisms of CR1’s sensitivity to microenvironmental or therapy associated stress, to determine the role of novel signal mediators, and to uncover targetable molecular underpinnings of the reprogramming that CR1 coordinates between cancer cells and their neighbors during breast cancer progression. To this end in Aim 1, we utilize a series of mouse transplant models (including patient derived breast cancer cells) and bioengineered systems to examine CR1 dependent cell state change at different stages of metastasis, and to test the effect of blocking CR1 on aggressive breast cancer phenotypes. In Aim 2, we will use multicellular culture systems to uncover the mechanics of CR1 signaling including its dependence on stress related upstream and downstream mediators, and cellular cross-talk. Both aims leverage our experience in single cell RNA-sequencing to elucidate cell state change at high resolution. Impact: This work will not only bring new understanding to the molecular biology of breast cancer cell plasticity and heterogeneity, but will also set the stage for clinical translational studies of CR1 blocking agents with newly defined targets, readouts and biomarkers at single cell resolution.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $435,802 )
2026	2026	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Biology Research	000	2	3/4/2026	NON-COMPETING CONTINUATION	$435,802
														Subtotal = $435,802

Issue Date FY: 2025 ( Subtotal = $472,921 )
2025	2025	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Biology Research	000	1	1/23/2025	NEW	$472,921
														Subtotal = $472,921

Grand Total All Awards = $908,723

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Coordination of stress-adaptive cell states by CRIPTO in breast cancer heterogeneity and progression

Award Number: R01CA289704

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2025

PERIOD OF PERFORMANCE END DATE: 01/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer